Abstract
Polycystic ovary syndrome (PCOS) is a common endocrine condition in women that causes adverse reproductive and metabolic effects. PCOS is a heterogeneous disorder and its pathogenesis is affected by different factors. Thus, the criteria for diagnosing PCOS, disease and availability of treatment options vary widely across different countries. Lidocaine has been proven to inhibit the proliferation of a variety of cancer cell types, and can be used alone or in combination with other drugs for the treatment of numerous types of disease. The present study aimed to determine whether lidocaine was able to reduce human ovarian granulosa cell tumor cell line KGN cell proliferation and provide a novel insight into potential therapeutic strategies for PCOS. KGN cells were treated alone with lidocaine at different concentrations, or with lidocaine and insulin-like growth factor-1 (IGF-1; a phosphoinositide 3-kinase (PI3K)/Protein kinase B (AKT) signaling pathway agonist) in combination for 48 h. The proliferative ability of KGN cells was detected using an 3-(45)-dimethylthiahiazo (-z-y1)-35-di- phenytetrazoliumromide (MTT) assay, and cell apoptosis was detected using flow cytometry. The expression levels of proteins and mRNAs were measured using western blotting and reverse transcription-quantitative polymerase chain reaction (RT-qPCR), respectively. The results of the present study revealed that lidocaine significantly suppressed KGN cell proliferation and increased apoptosis. Lidocaine significantly downregulated the protein expression levels of phosphorylated (p)-AKT and p-mTOR, but had no effect on their transcriptional levels. Treatment with IGF-1, could reverse the lidocaine-induced abnormal expression of PI3K/AKT signaling pathway-related proteins. Moreover, treatment with IGF-1 could reverse all the effects of lidocaine on KGN cells. In conclusion, the findings of the present study indicated that lidocaine may inhibit KGN cell proliferation and induce apoptosis by inhibiting the activation of the PI3K/AKT/mTOR signaling pathway. These results revealed the potential inhibitory effect of lidocaine on the proliferation of KGN cells and its underlying mechanism of action, providing a novel insight into potential therapeutic strategies for PCOS.
Similar content being viewed by others
Data availability
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
References
Abuelezz NZ, Shabana ME, Abdel-Mageed HM, Rashed L, Morcos GNB (2020) Nanocurcumin alleviates insulin resistance and pancreatic deficits in polycystic ovary syndrome rats: Insights on PI3K/AkT/mTOR and TNF-α modulations. Life Sci 256:118003
Abuelezz NZ, Shabana E, Rashed L, Morcos G (2021) Nanocurcumin modulates miR-223–3p and NF-κB levels in the pancreas of rat model of polycystic ovary syndrome to attenuate autophagy flare, insulin resistance and improve ß cell mass. J Exp Pharmacol 13:873–888
Beaussier M, Delbos A, Maurice-Szamburski A, Ecoffey C, Mercadal L (2018) Perioperative use of intravenous lidocaine. Drugs 78:1229–1246
Ben-Shlomo I, Younis JS (2014) Basic research in PCOS: are we reaching new frontiers? Reprod Biomed Online 28:669–683
Cai Z, He S, Li T, Zhao L, Zhang K (2020) Plumbagin inhibits proliferation and promotes apoptosis of ovarian granulosa cells in polycystic ovary syndrome by inactivating PI3K/Akt/mTOR pathway. Anim Cells Syst 24:197–204
Chang AY, Oshiro J, Ayers C, Auchus RJ (2016) Influence of race/ethnicity on cardiovascular risk factors in polycystic ovary syndrome, the Dallas Heart Study. Clin Endocrinol 85:92–99
Chi XX, Zhang T, Chu XL, Zhen JL, Zhang DJ (2018) The regulatory effect of Genistein on granulosa cell in ovary of rat with PCOS through Bcl-2 and Bax signaling pathways. J Vet Med Sci 80:1348–1355
Copp T, Hersch J, Muscat DM, McCaffery KJ, Doust J, Dokras A, Mol BW, Jansen J (2019) The benefits and harms of receiving a polycystic ovary syndrome diagnosis: a qualitative study of women's experiences. Hum Reprod Open 2019: hoz026.
Dietrich JB (1997) Apoptosis and anti-apoptosis genes in the Bcl-2 family. Arch Physiol Biochem 105:125–135
Han Q, Zhang W, Meng J, Ma L, Li A (2018) LncRNA-LET inhibits cell viability, migration and EMT while induces apoptosis by up-regulation of TIMP2 in human granulosa-like tumor cell line KGN. Biomed Pharmacother 100:250–256
Hanson MA, Gluckman PD (2014) Early developmental conditioning of later health and disease: physiology or pathophysiology? Physiol Rev 94:1027–1076
Hong B, He J, Le Q, Bai K, Chen Y, Huang W (2019) Combination formulation of tetrodotoxin and lidocaine as a potential therapy for severe arrhythmias. Mar Drugs 17:685
Izdebska M, Hałas-Wiśniewska M, Zielińska W, Klimaszewska-Wiśniewska A, Grzanka D, Gagat M (2019) Lidocaine induces protective autophagy in rat C6 glioma cell line. Int J Oncol 54:1099–1111
Jin L, Ren L, Lu J, Wen X, Zhuang SY, Geng T, Zhang YZ (2021) CXCL12 and its receptors regulate granulosa cell apoptosis in PCOS rats and human KGN tumor cells. Reproduction 161:145–157
Jourdan JP, Bureau R, Rochais C, Dallemagne P (2020) Drug repositioning: a brief overview. J Pharm Pharmacol 72:1145–1151
Jurj A, Tomuleasa C, Tat TT, Berindan-Neagoe I, Vesa SV, Ionescu DC (2017) Antiproliferative and apoptotic effects of lidocaine on human hepatocarcinoma cells. A preliminary study. J Gastrointestin Liver Di 26:45–50
Kamiya Y, Ohta K, Kaneko Y (2005) Lidocaine-induced apoptosis and necrosis in U937 cells depending on its dosage. Biomed Res 26:231–239
Klein JA, Jeske DR (2016) Estimated maximal safe dosages of tumescent lidocaine. Anesth Analg 122:1350–1359
Li S, Zhu D, Duan H, Tan Q (2013) Genetic investigation into ethnic disparity in polycystic ovarian syndrome. Gynecol Endocrinol 29:878–882
Li K, Yang J, Han X (2014a) Lidocaine sensitizes the cytotoxicity of cisplatin in breast cancer cells via up-regulation of RARβ2 and RASSF1A demethylation. Int J Mol Sci 15:23519–23536
Li H, Xu J, Wang X, Yuan G (2014b) Protective effect of ginsenoside Rg1 on lidocaine-induced apoptosis. Mol Med Rep 9:395–400
Li L, Mo H, Zhang J, Zhou Y, Peng X, Luo X (2016) The role of heat shock protein 90B1 in patients with polycystic ovary syndrome. PLoS ONE 11:e0152837
Li T, Mo H, Chen W et al (2017) Role of the PI3K-Akt signaling pathway in the pathogenesis of polycystic ovary syndrome. Reprod Sci 24:646–655
Li M, Zhao H, Zhao SG, Wei DM, Zhao YR, Huang T, Muhammad T, Yan L, Gao F, Li L, Lu G, Chan WY, Leung PCK, Dunaif A, Liu HB, Chen ZJ (2019) The HMGA2-IMP2 pathway promotes granulosa cell proliferation in polycystic ovary syndrome. J Clin Endocrinol Metab 104:1049–1059
Lim S, Smith CA, Costello MF, MacMillan F, Moran L, Ee C (2019) Barriers and facilitators to weight management in overweight and obese women living in Australia with PCOS: a qualitative study. BMC Endocr Disord 19:106
Liu Z, Ren YA, Pangas SA, Adams J, Zhou W, Castrillon DH, Wilhelm D, Richards JS (2015) FOXO1/3 and PTEN depletion in granulosa cells promotes ovarian granulosa cell tumor development. Mol Endocrinol 29:1006–1024
Liu WP, Chen Q, Liu ZD, Weng ZW, Nguyen TN, Feng JM, Zhou SH (2021) Zihuai recipe alleviates cyclophosphamide-induced diminished ovarian reserve via suppressing PI3K/AKT-mediated apoptosis. J Ethnopharmacol 277:113789
Liu H, Dilger JP, Lin J (2021) Lidocaine suppresses viability and migration of human breast cancer cells: TRPM7 as a target for some breast cancer cell lines. Cancers 13:234
Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCt method. Methods 25:402–408
Meier RK (2018) Polycystic ovary syndrome. Nurs Clin North Am 53:407–420
Nishi Y, Yanase T, Mu Y, Oba K, Ichino I, Saito M, Nomura M, Mukasa C, Okabe T, Goto K, Takayanagi R, Kashimura Y, Haji M, Nawata H (2001) Establishment and characterization of a steroidogenic human granulosa-like tumor cell line, KGN, that expresses functional follicle-stimulating hormone receptor. Endocrinology 142:437–445
Rong L, Li Z, Leng X, Li H, Ma Y, Chen Y, Song F (2020) Salidroside induces apoptosis and protective autophagy in human gastric cancer AGS cells through the PI3K/Akt/mTOR pathway. Biomed Pharmacother 122:109726
Rosenfield RL, Ehrmann DA (2016) The pathogenesis of polycystic ovary syndrome (PCOS): the hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocr Rev 37:467–520
Ruddenklau A, Campbell RE (2019) Neuroendocrine impairments of polycystic ovary syndrome. Endocrinology 160:2230–2242
Slaton RM, Thomas RH, Mbathi JW (2013) Evidence for therapeutic uses of nebulized lidocaine in the treatment of intractable cough and asthma. Ann Pharmacother 47:578–585
Song Y, Yu G, Xiang Y, Li Y, Wan L, Tan L (2019) Altered miR-186 and miR-135a contribute to granulosa cell dysfunction by targeting ESR2: A possible role in polycystic ovary syndrome. Mol Cell Endocrinol 494:110478
Truesdale K, Jurdi A (2013) Nebulized lidocaine in the treatment of intractable cough. Am J Hosp Palliat Care 30:587–589
Wang HW, Wang LY, Jiang L, Tian SM, Zhong TD, Fang XM (2016) Amide-linked local anesthetics induce apoptosis in human non-small cell lung cancer. J Thorac Dis 8:2748–2757
Wang M, Sun J, Xu B, Chrusciel M, Gao J, Bazert M, Stelmaszewska J, Xu Y, Zhang H, Pawelczyk L, Sun F, Tsang SY, Rahman N, Wolczynski S, Li X (2018) Functional characterization of MicroRNA-27a-3p expression in human polycystic ovary syndrome. Endocrinology 159:297–309
Wang Z, Liu Q, Lu J, Cao J, Wang XY, Chen Y (2020) Lidocaine promotes autophagy of SH-SY5Y cells through inhibiting PI3K/AKT/mTOR pathway by upregulating miR-145. Toxicol Res 9:467–473
Weibel S, Jelting Y, Pace NL, Helf A, Eberhart LH, Hahnenkamp K, Hollmann MW, Poepping DM, Schnabel A, Kranke P (2018) Continuous intravenous perioperative lidocaine infusion for postoperative pain and recovery in adults. Cochrane Database Syst Rev 6:009642
Werdehausen R, Braun S, Essmann F, Schulze-Osthoff K, Walczak H, Lipfert P, Stevens MF (2007) Lidocaine induces apoptosis via the mitochondrial pathway independently of death receptor signaling. Anesthesiology 107:136–143
Wu C, Jiang F, Wei K, Jiang Z (2018) Exercise activates the PI3K-AKT signal pathway by decreasing the expression of 5α-reductase type 1 in PCOS rats. Sci Rep 8:7982
Wu G, Xia J, Yang Z, Chen Y, Jiang W, Yin T, Yang J (2020) CircASPH promotes KGN cells proliferation through miR-375/MAP2K6 axis in polycystic ovary syndrome. J Cell Mol Med 00:1–9
Xia H, Zhao Y (2020) miR-155 is high-expressed in polycystic ovarian syndrome and promotes cell proliferation and migration through targeting PDCD4 in KGN cells. Artif Cells Nanomed Biotechnol 48:197–205
Xu W, Tang M, Wang J, Wang L (2020) Identification of the active constituents and significant pathways of cangfu daotan decoction for the treatment of PCOS based on network pharmacology. Evid Based Complement Alternat Med 2020:4086864
Yang X, Zhao L, Li M, Yan L, Zhang S, Mi Z, Ren L, Xu J (2018) Lidocaine enhances the effects of chemotherapeutic drugs against bladder cancer. Sci Rep 8:598
Yang D, Wang Y, Zheng Y, Dai F, Liu S, Yuan M, Deng Z, Bao A, Cheng Y (2021) Silencing of lncRNA UCA1 inhibited the pathological progression in PCOS mice through the regulation of PI3K/AKT signaling pathway. J Ovarian Res 14:48
Ye L, Zhang Y, Chen YJ, Liu Q (2019) Anti-tumor effects of lidocaine on human gastric cancer cells in vitro. Bratisl Lek Listy 120:212–217
Zhang L, Hu R, Cheng Y, Wu X, Xi S, Sun Y, Jiang H (2017) Lidocaine inhibits the proliferation of lung cancer by regulating the expression of GOLT1A. Cell Prolif 50:e12364
Zhang Y, Jia J, Jin W, Cao J, Fu T, Ma D, Zhang Y (2020) Lidocaine inhibits the proliferation and invasion of hepatocellular carcinoma by downregulating USP14 induced PI3K/Akt pathway. Pathol Res Pract 216:152963
Zhang N, Liu X, Zhuang L, Liu X, Zhao H, Shan Y, Liu Z, Li F, Wang Y, Fang J (2020) Berberine decreases insulin resistance in a PCOS rats by improving GLUT4: Dual regulation of the PI3K/AKT and MAPK pathways. Regul Toxicol Pharmacol 110:104544
Zhao H, Zhou D, Chen Y, Liu D, Chu S, Zhang S (2017) Beneficial effects of Heqi san on rat model of polycystic ovary syndrome through the PI3K/AKT pathway. Daru 25:21
Zhao L, Ma N, Liu G, Mao N, Chen F, Li J (2021) Lidocaine inhibits hepatocellular carcinoma development by modulating circ_ITCH/miR-421/CPEB3 axis. Dig Dis Sci 66:4384–4397
Zheng W, Nagaraju G, Liu Z, Liu K (2012) Functional roles of the phosphatidylinositol 3-kinases (PI3Ks) signaling in the mammalian ovary. Mol Cell Endocrinol 356:24–30
Zheng Y, Hou X, Yang S (2019) Lidocaine potentiates SOCS3 to attenuate inflammation in microglia and suppress neuropathic pain. Cell Mol Neurobiol 39:1081–1092
Acknowledgements
Not applicable.
Funding
No funding was received.
Author information
Authors and Affiliations
Contributions
HX and QH contributed to the study design, data collection, statistical analysis, data interpretation and manuscript preparation. QJ contributed to data collection, statistical analysis and manuscript preparation. HX and QH confirm the authenticity of all the raw data. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no competing interests.
Ethical approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Xiong, H., Hu, Q. & Jiang, Q. Protective effects of lidocaine on polycystic ovary syndrome through modulating ovarian granulosa cell physiology via PI3K/AKT/mTOR pathway. Cytotechnology 74, 283–292 (2022). https://doi.org/10.1007/s10616-022-00528-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10616-022-00528-0